Fluidigm Corp
NASDAQ:FLDM
Intrinsic Value
Fluidigm Corp. is engaged in the development, manufacture, and marketing of biotechnology tools for life sciences research. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of FLDM.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Fluidigm Corp's business.
What risks and challenges
does Fluidigm Corp face in the near future?
Summarize the latest earnings report
of Fluidigm Corp.
Provide P/E
for Fluidigm Corp and its competitors.
Balance Sheet Decomposition
Fluidigm Corp
Current Assets | 72.1m |
Cash & Short-Term Investments | 28.5m |
Receivables | 18.3m |
Other Current Assets | 25.3m |
Non-Current Assets | 203.1m |
PP&E | 65.2m |
Intangibles | 29.2m |
Other Non-Current Assets | 108.8m |
Current Liabilities | 49.6m |
Accounts Payable | 10.6m |
Accrued Liabilities | 16.6m |
Other Current Liabilities | 22.3m |
Non-Current Liabilities | 131.1m |
Long-Term Debt | 64.2m |
Other Non-Current Liabilities | 66.8m |
Earnings Waterfall
Fluidigm Corp
Revenue
|
130.6m
USD
|
Cost of Revenue
|
-61.2m
USD
|
Gross Profit
|
69.4m
USD
|
Operating Expenses
|
-136.8m
USD
|
Operating Income
|
-67.5m
USD
|
Other Expenses
|
8.2m
USD
|
Net Income
|
-59.2m
USD
|
Free Cash Flow Analysis
Fluidigm Corp
What is Free Cash Flow?
FLDM Profitability Score
Profitability Due Diligence
Fluidigm Corp's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Fluidigm Corp's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
FLDM Solvency Score
Solvency Due Diligence
Fluidigm Corp's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Score
Fluidigm Corp's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FLDM Price Targets Summary
Fluidigm Corp
Ownership
FLDM Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
FLDM Price
Fluidigm Corp
Average Annual Return | 1.72% |
Standard Deviation of Annual Returns | 106.17% |
Max Drawdown | -91% |
Market Capitalization | 285.4m USD |
Shares Outstanding | 77 198 600 |
Percentage of Shares Shorted | 8.46% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Fluidigm Corp. is engaged in the development, manufacture, and marketing of biotechnology tools for life sciences research. The company is headquartered in South San Francisco, California and currently employs 615 full-time employees. The company went IPO on 2011-02-10. The firm operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. The company markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits (ifcs), assays, and reagents. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.